Reason for request
Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals
Clinical Benefit
| Substantial |
The actual benefit of DIACOMIT is substantial. |
Clinical Added Value
| moderate |
DIACOMIT provides a moderate (level III) improvement in actual benefit in the management of patients with severe myoclonic epilepsy in infancy when the sodium valproate-clobazam combination does not provide adequate control. |
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
n4NyG1DRcxvqXR75
Listen
